# 2026-13144: Catalent Seeks DEA Nod to Import LSD and Psilocybin

2026-13144, Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2026-06-30, effective Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before July 30, 2026. Such persons may also file a written request for a hearing on the application on or before July 30, 2026.; PRIA reads it as touching household money (as of 2026-07-07).

- Canonical: https://policyrisk.com/federal-register/2026-13144
- As of: 2026-07-07
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-13144
- Title: Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 39636
- Published: 2026-06-30
- Effective: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before July 30, 2026. Such persons may also file a written request for a hearing on the application on or before July 30, 2026.
- Comments close: 2026-07-30
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-07

## In one line

Catalent Seeks DEA Nod to Import LSD and Psilocybin

## Summary

Catalent Pharma Solutions wants to become an official importer of some powerful controlled substances like LSD and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by July 30, 2026. This move could impact companies involved in these substances and the government’s control over them.

## Abstract

Catalent Pharma Solutions, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

## Effects PRIA read

- Catalent applied to import Schedule I drugs: benefit, low. Catalent Pharma Solutions applied on May 28, 2026 to be registered to import three Schedule I controlled substances: lysergic acid diethylamide (LSD, code 7315), 5‑Methoxy‑N‑N‑dimethyltryptamine (code 7431), and psilocybin (code 7437). The company says it plans to import finished dosage unit produc…
- Public comment and hearing deadline: benefit, low. Registered bulk manufacturers and applicants may submit electronic comments or objections, or file a written request for a hearing, on or before July 30, 2026. Comments must be submitted through https://www.regulations.gov and hearing requests must also be sent to the DEA addresses listed in the no…
- Import authorization limited — no commercial sales: cost, medium. If registered, Catalent's authorization would be limited to importing the listed substances as finished dosage unit products for clinical trials, research, and analytical activities only. The authorization will not extend to importing FDA‑approved or non‑approved finished dosage forms for commercia…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2026-13144 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/30/2026-13144/importer-of-controlled-substances-application-catalent-pharma-solutions-llc)
- [2026-13144 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-30/pdf/2026-13144.pdf)

## Related
- [Previous: 2026-13143, Agency Information Collection Activity Under OMB Review: Presidential Memorial…](https://policyrisk.com/federal-register/2026-13143)
- [Next: 2026-13145, Importer of Controlled Substances Application: Almac Clinical Services Incorp.…](https://policyrisk.com/federal-register/2026-13145)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-13144 (as of 2026-07-07).
